Denner is laser-beam focused on improving the strategies of companies to unlock shareholder value. If there is anyone who can turn around this ship, you can bet that's Mr. Now, when I read up on the Sarissa CIO ( Alex Denner), I realized that he is the turnaround catalyst needed for Amarin. Being a significant shareholder of Amarin, the Chief Investment Officer and Founder of Sarissa (i.e., Alex Denner, Ph.D.) and his team can make changes to the Board and thereby exert influences on corporate operations. As such, their total holding is worth roughly $28.3M. From the figure below you can see that the healthcare/biotech-focused Sarrisa Capital currently owns 23.9M shares (i.e., 5.9% of all shares outstanding). Specifically, Vascepa is approved for hypertriglyceridemia (i.e., elevated blood lipid) and for the reduction of cardiovascular risk in high-risk patients.įigure 2: Therapeutic pipeline Turnaround Strategy: Activism from Sarissa CapitalĪs you can appreciate, activist investing is crucial to the turnaround of your stock. For the sake of simplicity, I will refer to both Vascepa and Vazkepa as Vascepa. The company is commercializing a synthetic Omega-3 fatty acid known as icosapent ethyl: it is marketed as Vascepa in the US and Vazkepa in the EU. Operating out of Bridgewater New Jersey and Dublin Ireland, Amarin is engaged in the innovation and commercialization of medicine to serve the strong unmet needs in cardiovascular health. If you are familiar with the firm, I recommend that you skip to the next section. In this research, I'll feature a fundamental analysis of Amarin and share with you my expectations for this intriguing growth equity.Īs usual, I'll present a brief corporate overview for new investors. Interestingly, the activist investor titan (Alex Denner of Sarissa Capital) is flexing his muscles to rattle Amarin's Board. With the new Board, Amarin is trying to right the ship. In the subsequent years, the stock tumbled and lost most of its value. I used to follow Amarin but dropped the company back in early 2021 due to a key management departure. That being said, I'd like to revisit a turnaround stock dubbed Amarin Corporation ( NASDAQ: AMRN). Of various types of stock, turnaround equity is extremely risky yet it has tremendous return potential. Empowering with that market intelligence, you can make more prudent investment decisions. Those information gives you the risks and returns profile for your stock. More importantly, you need to know which business model the company is employing.
When you invest in biotech, you have to know what type of company you are holding.
Warren BuffettĪuthor's Note: This article is an abridged version of an article originally published for members of the Integrated BioSci Investing marketplace on October 13, 2022. We simply attempt to be fearful when others are greedy and to be greedy only when others are fearful.
0 kommentar(er)
